Faecal microbiota transplantation (FMT)

Challenges and opportunities for the treatment and prevention of recurrent C. difficile infection (rCDI) in Canada

Lucy Hocking, Gianluca Ianiro, Rupert W. Leong, Tariq Iqbal, Dina Kao, Mark Cabling, Stephanie Stockwell, Robert J. Romanelli, Sonja Marjanovic

Data VizPublished Sep 30, 2024

Cover: Faecal microbiota transplantation (FMT)
Download PDF
Additional Downloads

Includes Translations

Faecal microbiota transplantation (FMT) has emerged as a promising treatment for C. difficile infection (CDI), the most common nosocomial bacterial infection, which can lead to intestinal damage, sepsis and even death. While there is evidence that FMT is clinically effective for the treatment of recurrent CDI, there is a limited understanding of the diverse requirements for safe, effective, accessible and sustainable delivery of services. The objective of this research was to better understand the key components of FMT provision related to the patient care pathway, the stool donor pathway and the wider healthcare system.

Topics

Document Details

  • Copyright: Ferring Pharmaceuticals
  • Publisher: RAND Corporation
  • Availability: Web-Only
  • Year: 2024
  • Pages: 1
  • DOI: https://doi.org/10.7249/IGA3265-6
  • Document Number: IG-A3265-6

Citation

RAND Style Manual
Hocking, Lucy, Gianluca Ianiro, Rupert W. Leong, Tariq Iqbal, Dina Kao, Mark Cabling, Stephanie Stockwell, Robert J. Romanelli, and Sonja Marjanovic, Faecal microbiota transplantation (FMT): Challenges and opportunities for the treatment and prevention of recurrent C. difficile infection (rCDI) in Canada, RAND Corporation, IG-A3265-6, 2024. As of October 8, 2024: https://www.rand.org/pubs/infographics/IGA3265-6.html
Chicago Manual of Style
Hocking, Lucy, Gianluca Ianiro, Rupert W. Leong, Tariq Iqbal, Dina Kao, Mark Cabling, Stephanie Stockwell, Robert J. Romanelli, and Sonja Marjanovic, Faecal microbiota transplantation (FMT): Challenges and opportunities for the treatment and prevention of recurrent C. difficile infection (rCDI) in Canada. Santa Monica, CA: RAND Corporation, 2024. https://www.rand.org/pubs/infographics/IGA3265-6.html.
BibTeX RIS

Research conducted by

This study was funded by Ferring Pharmaceuticals and was independently conducted by RAND Europe.

This publication is part of the RAND infographic series. RAND infographics are design-focused, visual representations of data and information based on a published, peer-reviewed product or a body of published work.

All rights reserved. Only one copy of this document may be retained for personal non-commercial use. Otherwise no part of this document may be reproduced in any form by any electronic or mechanical means (including photocopying, recording, or information storage and retrieval) without permission in writing from Ferring Pharmaceuticals.

RAND is a nonprofit institution that helps improve policy and decisionmaking through research and analysis. RAND's publications do not necessarily reflect the opinions of its research clients and sponsors.